Abrucomstat is primarily researched for its potential application in the treatment of Alzheimer's disease. It functions as a selective inhibitor of the enzyme butyrylcholinesterase, which is involved in the breakdown of acetylcholine, a neurotransmitter crucial for memory and learning. By inhibiting this enzyme, Abrucomstat aims to increase acetylcholine levels in the brain, thereby improving cognitive function in patients with Alzheimer's. Its targeted mechanism offers a promising approach to managing symptoms and potentially slowing disease progression, making it a significant focus in neurodegenerative disorder research.